Exclusive: FDA Nicotine Pouch Pilot to Ease Research Burden on Manufacturers, Transcript Shows

The U.S. Food and Drug Administration (FDA) will ease certain requirements for nicotine pouch makers under a new pilot program, according to internal meeting transcripts reviewed by Reuters—marking the first clear sign of a softer Trump White House stance on cigarette alternatives.

Traditionally, the FDA has required rigorous testing of all new nicotine products before they can be sold in the U.S., including costly studies demonstrating their population-level health impact. The agency’s goal has been to ensure such products provide a net public health benefit—helping smokers quit without sparking new problems, such as youth uptake.

But under the pilot, discussed in an early September internal meeting, the FDA will waive the need for product-specific studies in several areas. Instead, the agency will rely on existing general research about nicotine pouches—small packets placed under the lip for nicotine absorption. Notably, manufacturers will no longer need to submit prior studies on the effectiveness of pouches in reducing smoking rates.

The FDA confirmed some aspects of the pilot on Thursday, including faster timelines and more frequent communication with applicants, but stopped short of acknowledging the shift toward more generalized evidence in place of product-specific data.

While still in trial phase, the move signals a potential relaxation of what many consider one of the world’s toughest review regimes for smoking alternatives. Major tobacco companies—Philip Morris International, Altria, and British American Tobacco—often face years-long waits or outright rejections for FDA reviews. Their pouch brands, including Zyn, On!, and Velo, stand to benefit from the program.

Industry reaction has been cautious. PMI and Altria declined to comment before full details are released. BAT reiterated its long-standing call for streamlined regulation, calling it vital for U.S. public health.

FDA maintains it isn’t lowering standards

During the meeting, Brett Coplow, acting director of the FDA’s Center for Tobacco Products (CTP), said the pilot could help inform updates for other categories, including e-cigarettes, where the agency has so far taken a stricter stance. Coplow did not respond to Reuters’ request for comment.

HHS, which oversees the FDA, pointed to Coplow’s earlier remarks that there was no pressure from the Trump administration or agency leadership to lower scientific standards.

Even so, two former CTP directors stressed that product-specific studies remain critical. Brian King, who led CTP until April, said differences in nicotine strength or flavors could significantly affect how smokers or new users adopt pouches. Mitch Zeller, who served as CTP director until 2022, warned that the pilot risked a “careless” approach to youth use, noting parallels with the past surge of vaping among teenagers.

FDA officials acknowledged in the meeting that nicotine pouches appear lower-risk than other nicotine products—exposing users to fewer toxic chemicals—and that youth uptake has remained limited so far.

Mary Hrywna, a Rutgers University associate professor who studies nicotine products, told Reuters the shift could expand access to less harmful options for smokers. “Whether that actually motivates people to quit is a separate issue,” she noted.

Two tobacco industry analysts said a streamlined FDA process would likely accelerate growth in the already fast-expanding pouch market. But ARAC consultancy CEO Jessica Zdinak cautioned that, based on transcript details, clinical studies—including the most resource-intensive ones—will still be required, meaning applications will remain challenging.